Tyrosine kinase inhibitors

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
(Die Seite wurde neu angelegt: „ok some other kinases included... '''PAK-1 target''' {{tp|p=32313880|t=ä. PAK1-blockers: Potential Therapeutics against COVID-19? |pdf=|usr=}} {{tp|p=3234887…“)
 
K
 
(3 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
ok some other kinases included...
+
{{up|PHA conventional pharmacology}}
 +
 
 +
 
 +
'''mixed retargeted oncopharmaceuticals'''
 +
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
  
 
'''PAK-1 target'''
 
'''PAK-1 target'''
Zeile 8: Zeile 13:
 
'''Imatinib'''
 
'''Imatinib'''
 
{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
 
{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
 
+
{{tp|p=32599278|t=2020. Imatinib for COVID-19: A case report.|pdf=|usr=011}}
  
 
'''BTK Bruton Tyrosine Kinase''' ''ibrutiib''
 
'''BTK Bruton Tyrosine Kinase''' ''ibrutiib''
Zeile 14: Zeile 19:
 
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
 
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
 
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
 
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
 
+
{{ttp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}}
  
 
'''akt PKB'''
 
'''akt PKB'''
Zeile 21: Zeile 26:
 
'''Abelson tyrosine kinase'''
 
'''Abelson tyrosine kinase'''
 
{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
 
{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
 
+
{{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}}
  
 
'''p38 mapk'''
 
'''p38 mapk'''
 
{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}
 
{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}

Aktuelle Version vom 18. Januar 2021, 20:26 Uhr

PHA conventional pharmacology


mixed retargeted oncopharmaceuticals

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1


Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19
32599278 2020. Imatinib for COVID-19: A case report.

BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.

akt PKB
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?

Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.

p38 mapk
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis